-
Subject Areas on Research
-
A Phase 1 Study of Intravitreous E10030 in Combination with Ranibizumab in Neovascular Age-Related Macular Degeneration.
-
A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial.
-
A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity.
-
A hybrid DNA aptamer-dendrimer nanomaterial for targeted cell labeling.
-
A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release.
-
A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders.
-
A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery.
-
A nuclease-resistant RNA aptamer specifically inhibits angiopoietin-1-mediated Tie2 activation and function.
-
A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent.
-
A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial.
-
A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor.
-
A reversible aptamer improves outcome and safety in murine models of stroke and hemorrhage.
-
An anticoagulant RNA aptamer that inhibits proteinase-cofactor interactions within prothrombinase.
-
Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers.
-
Anti-factor IXa Aptamer reduces propagation of thrombin generation in plasma anticoagulated with warfarin.
-
Antidote control of aptamer therapeutics: the road to a safer class of drug agents.
-
Antidote-controlled antithrombotic therapy targeting factor IXa and von Willebrand factor.
-
Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers.
-
Antimetastatic potential of PAI-1-specific RNA aptamers.
-
Aptamer applications for targeted cancer therapy.
-
Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells.
-
Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells.
-
Aptamers Coming of Age at Twenty-Five.
-
Aptamers as Reversible Sorting Ligands for Preparation of Cells in Their Native State.
-
Aptamers as Therapeutics.
-
Aptamers in immunotherapy.
-
Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis.
-
Aptamers: an emerging class of therapeutics.
-
C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.
-
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.
-
Cell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cells.
-
Cell-specific aptamers for targeted therapies.
-
Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass.
-
Combining Heparin and a FX/Xa Aptamer to Reduce Thrombin Generation in Cardiopulmonary Bypass and COVID-19.
-
Conformationally selective RNA aptamers allosterically modulate the β2-adrenoceptor.
-
Crystal structure of an RNA aptamer bound to thrombin.
-
Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers.
-
Development of universal antidotes to control aptamer activity.
-
Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia.
-
Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design.
-
Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration: A Phase IIb, Multicenter, Randomized Controlled Trial.
-
Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial.
-
Effects of plasminogen activator inhibitor-1-specific RNA aptamers on cell adhesion, motility, and tube formation.
-
Efficient detection of RNA-protein interactions using tethered RNAs.
-
Emerging applications of aptamers for anticoagulation and hemostasis.
-
EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model.
-
Factor IXa as a target for pharmacologic inhibition in acute coronary syndrome.
-
Factor IXa inhibitors as novel anticoagulants.
-
First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention.
-
First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.
-
Further characterization of the target of a potential aptamer biomarker for pancreatic cancer: cyclophilin B and its posttranslational modifications.
-
Gene therapy progress and prospects: RNA aptamers.
-
Generation and characterization of aptamers targeting factor XIa.
-
Generation of an anticoagulant aptamer that targets factor V/Va and disrupts the FVa-membrane interaction in normal and COVID-19 patient samples.
-
H1 RNA polymerase III promoter-driven expression of an RNA aptamer leads to high-level inhibition of intracellular protein activity.
-
Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40.
-
Identification of liver cancer-specific aptamers using whole live cells.
-
In vivo selection of tumor-targeting RNA motifs.
-
In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry.
-
Increased anticoagulant activity of thrombin-binding DNA aptamers by nanoscale organization on DNA nanostructures.
-
Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer.
-
Inhibition of factor IXa by the pegnivacogin system during cardiopulmonary bypass: a potential substitute for heparin. A study in baboons.
-
Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer.
-
Modulation of the Coagulation Cascade Using Aptamers.
-
Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice.
-
NF-kappaB inhibition by an adenovirus expressed aptamer sensitizes TNFalpha-induced apoptosis.
-
Nucleic acid aptamers as adjuncts to vaccine development.
-
Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics.
-
Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration.
-
Osteopontin regulates epithelial mesenchymal transition-associated growth of hepatocellular cancer in a mouse xenograft model.
-
PEG-Like Brush Polymer Conjugate of RNA Aptamer That Shows Reversible Anticoagulant Activity and Minimal Immune Response.
-
Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy.
-
Pericyte requirement for anti-leak action of angiopoietin-1 and vascular remodeling in sustained inflammation.
-
Pharmacokinetic characterization of an RNA aptamer against osteopontin and demonstration of in vivo efficacy in reversing growth of human breast cancer cells.
-
Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease.
-
Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer.
-
Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer.
-
Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels.
-
Programming DNA-Based Biomolecular Reaction Networks on Cancer Cell Membranes.
-
Progression of choroidal neovascularization following injection of pegaptanib sodium (macugen) in two eyes with neovascular age-related macular degeneration.
-
Pseudouridines have context-dependent mutation and stop rates in high-throughput sequencing.
-
REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis.
-
REGULATE-PCI trial--Author's reply.
-
RNA Aptamer-targeted Inhibition of NF-κB Suppresses Non-small Cell Lung Cancer Resistance to Doxorubicin.
-
RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells.
-
RNA aptamer therapy for vaso-occlusion in sickle cell disease.
-
RNA aptamer-based functional ligands of the neurotrophin receptor, TrkB.
-
RNA inhibitors of nuclear proteins responsible for multiple organ dysfunction syndrome.
-
Rapid identification of cell-specific, internalizing RNA aptamers with bioinformatics analyses of a cell-based aptamer selection.
-
Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor.
-
Regulatable aptamers in medicine: focus on antithrombotic strategies.
-
Serum protein profiling using an aptamer array predicts clinical outcomes of stage IIA colon cancer: A leave-one-out crossvalidation.
-
Simple and sensitive aptamer-based colorimetric sensing of protein using unmodified gold nanoparticle probes.
-
Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection.
-
Six-week outcomes after pegaptanib.
-
Smooth Muscle Cell-targeted RNA Aptamer Inhibits Neointimal Formation.
-
Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin.
-
Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.
-
Targeted disruption of β-arrestin 2-mediated signaling pathways by aptamer chimeras leads to inhibition of leukemic cell growth.
-
Targeted inhibition of alphavbeta3 integrin with an RNA aptamer impairs endothelial cell growth and survival.
-
Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant.
-
Targeting inhibition of GluR1 Ser845 phosphorylation with an RNA aptamer that blocks AMPA receptor trafficking.
-
The development and testing of aptamers for cancer.
-
The effect of surface contact activation and temperature on plasma coagulation with an RNA aptamer directed against factor IXa.
-
The effect of the REG2 Anticoagulation System on thrombin generation kinetics: a pharmacodynamic and pharmacokinetic first-in-human study.
-
The role of antigen specificity in the binding of murine monoclonal anti-DNA antibodies to microparticles from apoptotic cells.
-
The role of carrier size in the pharmacodynamics of antisense and siRNA oligonucleotides.
-
The role of osteopontin and osteopontin aptamer (OPN-R3) in fibroblast activity.
-
Therapeutic Aptamers: Evolving to Find their Clinical Niche.
-
Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine.
-
Translation and Clinical Development of Antithrombotic Aptamers.
-
Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer.
-
Ultrasensitive colorimetric detection of protein by aptamer-Au nanoparticles conjugates based on a dot-blot assay.
-
Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study.
-
Keywords of People
-
Alexander, John Hunter Peel,
Professor of Medicine,
Medicine, Cardiology
-
Hoffman, Maureane,
Professor of Pathology,
Immunology
-
Miller Jr., Francis Joseph,
Adjunct Professor in the Department of Medicine,
Medicine, Cardiology
-
Mruthyunjaya, Prithvi,
Adjunct Associate Professor in the Department of Ophthalmology,
Ophthalmology, Vitreoretinal Diseases & Surgery